| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Hydroxyprogesterone in Spironolactone-Treated HypertensivesDepartment of Internal Medicine, Medical College of Ohio Toledo, Ohio
Reprint requests to: Dr. S. Y. Tan, Department of Internal Medicine, Medical College of Ohio, P.O. Box 6190, Toledo, Ohio 43614.
When measured by a specific radioassay method which excludes drug interference, plasma 17
-hydroxyprogesterone levels were found to be similar in spironolactone treated hypertensives, in untreated hypertensives, and in normotensive volunteers. No in vivo evidence for a significant inhibitory effect of spironolactone on adrenal 11β, 17
and 21 hydroxylases was uncovered.
Nomenclature: Spironolactone: 17β-hydroxy-7
-acetylthio-3-oxo-pregn-4-ene-21-carboxylic acid,
lactone; Canrenone: 17β-hydroxy-3-oxo-pregna-4, 6-diene-21-carboxylic acid,
lactone; K% Canrenoate: 17β-hydroxy-3-oxo-pregna-4, 6-diene-21-carboxylic acid, potassium salt; Metabolite X: 6β, 17β-dihydroxy-7
-methylsulfinyl-3-oxo-pregn-4-ene-21-carboxylic acid,
lactone; SC 26519: 17β-hydroxy-7
-methylthio-3-oxo-pregn-4-ene-21-carboxylic acid,
lactone; SC 26780: 17β-hydroxy-7
-methylsulfinyl-3-oxo-pregn- 4-ene-21-carboxylic acid,
lactone; SC 24813: 17β-hydroxy - 7
- mercapto - 3 - oxo - pregn - 4 - ene - 21-carboxylic acid,
lactone.
Received February 17, 1976.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |